Volumen 17 número 2 - Agosto 2020
ISSN 0718-0918
Tabla de Contenidos > Actualización

USO CONVENCIONAL DE SURFACTANTE EN RECIEN NACIDOS CON ENFERMEDAD DE MEMBRANA HIALINA
Dr. Germán Mühlhausen Muñoz.
Pediatra Neonatologo - Hospital San José
Profesor Asociado (D)
Departamento de Pediatría y Cirugía Infantil
Facultad de Medicina Universidad de Chile

Resumen |Abstract | Texto completo | Descargar cuerpo en pdf

Hyaline membrane disease is due to surfactant deficiency in the lungs of newborns, especially those younger than 37 weeks gestation. Maternal management with prenatal corticosteroids in this group reduces the morbidity and mortality associated with this neonatal pathology. The administration of surfactant to these preterm infants is analyzed from the point of the currently existing evidence and the type of surfactant to be administered is reviewed, when is the best time to administer it, the dose and the form of administration.

Key words Surfactant, Hyaline membrane disease, Antenatal corticosteroid therapy.